General Announcement::GPL Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
26-Jul-2018 11:20:08
Status
New
Announcement Sub Title
GPL Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310
Announcement Reference
SG180726OTHR862X
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
26/07/2018 08:47:00
Description (Please provide a detailed description of the event in the box below)
Sub: Glenmark Pharmaceuticals Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310 Compared to the Reference Product Omalizumab

Attachments

PR_26072018.pdf
Total size =3222K